- 公司资讯
- finviz | 2020年03月11日 04:01Sophiris Bio Announces Nasdaq Delisting
- finviz | 2019年11月18日 18:20SPHS: Single Phase 3 Clinical Trial Planned for Topsalysin in Localized Prostate Cancer
- finviz | 2019年11月08日 04:05Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
- finviz | 2019年10月21日 20:00Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
- finviz | 2019年08月30日 20:00Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
- finviz | 2019年08月30日 20:00Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
- finviz | 2019年08月27日 23:05SPHS: Awaiting Feedback from FDA on Phase 3 Plan for Topsalysin in Prostate Cancer
- finviz | 2019年08月27日 20:00Sophiris Bio Announces $4.0 Million Registered Direct Offering
- finviz | 2019年08月09日 20:00Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
- finviz | 2019年06月20日 21:50SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback
- finviz | 2019年06月19日 20:30Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
- finviz | 2019年06月14日 19:21Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
- finviz | 2019年05月14日 21:30SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19
- finviz | 2019年05月10日 04:05Sophiris Bio Reports First Quarter 2019 Financial Results
- finviz | 2019年04月03日 04:05Sophiris Bio to Present at Two Upcoming Investor Conferences
- finviz | 2019年03月29日 23:45SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study
首页
上页
下页